kchristoffersen | GlobeImmune

GlobeImmune’s GI-4000 in Combination with Gemcitabine Following Surgery Shows Evidence of an Improvement in Survival in a Phase 2b Clinical Trial with Ras Mutation Positive Pancreas Cancer

June 27, 2012

Phase 2b Survival Data of R1 Resection Subjects Presented at ESMO 14th World Congress on Gastrointestinal Cancer BARCELONA, Spain, June 27, 2012 – GlobeImmune, Inc., today announced that GI-4000 in combination with gemcitabine showed evidence of an improvement in overall survival … Continue reading →

GlobeImmune Initiates Phase 1 Clinical Trial of GI-6301 in Brachyury Expressing Cancers

February 08, 2012

GI-6301 is GlobeImmune’s third oncology Tarmogen® product to begin human clinical trials LOUISVILLE, Colo., Feb. 8, 2012 – GlobeImmune, Inc. today announced the initiation of a Phase 1 clinical trial to be conducted at the National Cancer Institute (NCI) to … Continue reading →

Gilead and GlobeImmune Announce License and Collaboration Agreement to Develop Therapeutic Vaccine Products For Treatment of Chronic Hepatitis B Infection

October 24, 2011

Foster City, CA and Louisville, CO – October 24, 2011 – Gilead Sciences, Inc. (Nasdaq: GILD) and GlobeImmune, Inc. today announced that the companies have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of … Continue reading →

GlobeImmune Promotes Jeffrey Dekker to Vice President of Finance

August 31, 2011

LOUISVILLE, Colo., Aug. 31, 2011 – GlobeImmune Inc. announced today the promotion of Jeffrey Dekker to Vice President of Finance. Mr. Dekker previously served as Controller and Senior Director Finance at GlobeImmune since joining the company in 2006. Before joining … Continue reading →

GlobeImmune Reports Positive Results for Two Therapeutic Vaccines, GI-4000 and GI-6207

June 01, 2011

Oncology data to be presented at the 2011 annual meeting of the American Society of Clinical Oncology (ASCO)

Continue reading →